How CRISPR Is Rewriting Medicine Faster Than Regulators Can Follow
May 28, 2026 · Frisian News
Gene-editing company CRISPR Therapeutics has won approval for three treatments in two years, while regulatory agencies struggle to keep pace with the science. The speed raises questions about safety oversight and who decides which diseases deserve a cure.
In March 2026, CRISPR Therapeutics announced the FDA approval of another gene-editing therapy. Each treatment targets a rare blood disorder. The company now trades at a high market value, built largely on the promise that CRISPR can fix genetic diseases at their root. But the speed of approval raises a hard question: can the FDA actually track what happens after patients leave the clinic?
Regulatory agencies in America and Europe approved these therapies based on data from Phase 2 trials, not the larger Phase 3 studies that typically anchor a drug's safety record. The FDA compressed review timelines significantly. Regulators have acknowledged approving therapies without a full understanding of all possible off-target effects, the cuts that the genetic scissors make in the wrong places of the genome.
CRISPR Therapeutics spent money on lobbying in the United States, according to federal disclosure records. The company employed former FDA staffers. This is not illegal, but it raises an obvious point: the people who write the rules often leave government and work for the companies they once watched. The incentive to move fast flows downhill. When a company faces rare-disease patients with no other options, regulators feel pressure to say yes first and watch second.
The approvals also reveal a narrower problem. CRISPR Therapeutics targets sickle cell disease and beta thalassemia, both more common in African and Mediterranean populations. Yet the trials enrolled mostly white patients in wealthy countries. CRISPR's cures reach the rich. The poor get the press release.
Meanwhile, off-target effects have already shown up in real patients. As skeptics warned, regulators approved the therapy without full knowledge of what it does. The FDA cannot follow the speed of the science because the science moves faster than bureaucrats can read. That gap will only widen.
Published May 28, 2026 · Frisian News